A microbiota-derived bile acid controls hepatic cholesterol levels in cachectic mice

Our work showed decreased hepatic levels of TDCA in the C26 model of cancer cachexia. We also found gut microbiota composition alterations in cachectic C26 mice, as well as reductions in microbial 7a-dehydroxylase activity, and activity of 7a-HSDH and 12a-HSDH, which drive the production of secondary bile acids. Finally, we showed that TDCA administration induces lower hepatic levels of cholesterol in C26 mice. Published in Thibaut et al, Gut Microbes 2025 Overall design: Hepatic RNA profiles of sham-injected mice (CT, n=6), untreated C26-transplanted mice (C26, n=8) and C26-injected mice receiving daily intraperitoneal injection of taurodeoxycholic acid (C26-TDCA, 10 mg/kg, n=8)